We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Fructosamine Reference Range Established for Brazil

By LabMedica International staff writers
Posted on 14 Jan 2019
Traditional markers used in diabetes diagnosis and monitoring include fasting plasma glucose (FPG), two-hour plasma glucose (2-hPG) measured during the oral glucose tolerance test (OGTT), and glycated hemoglobin (HbA1c) levels.

The fructosamine test is used in the monitoring of diabetes mellitus, particularly in cases with restrictions on the use of glycated hemoglobin, mainly in the setting of altered red blood cell lifespan and interference by hemoglobin variants. More...
It could also provide additional information on shorter-term glycemic control.

Scientists at the Federal University of Minas Gerais, (Belo Horizonte, Brazil) collected blood samples from 2,288, that were part of a comprehensive study and available for fructosamine testing. The team excluded from the study individuals with a previous history of diabetes (n = 161), with FPG ≥ 5.6 mmol/L (100 mg/dL) and/or 2-hPG ≥ 7.8 mmol/L (140 mg/dL) and/or HbA1c ≥ 38.8 mmol/mol, (5.7%). They also excluded individuals with microalbuminuria ≥ 20 μg/min and creatinine> 114.9 µmol/L (1.3 mg/dL).

Samples were collected after a 12-h fasting period. The OGTT was conducted in all participants included in the present study. Samples were stored at −80 °C. Serum fructosamine levels were determined by the colorimetric nitroblue tetrazolium method in an AU 5800 automatic analyzer. The scientists proposed that the reference interval should be 186 to 248 μmol/L for women and 196 to 269 μmol/L for men. Fructosamine levels were higher in men than in women and in the non-white population and had a negative correlation with the body mass index.

The authors concluded that their study represents the first effort to establish a reference range for fructosamine levels in the Brazilian population. The report, which used the ELSA-Brazil baseline as a source of data, might contribute to future work on the diagnosis and monitoring of diabetes mellitus (DM), especially in situations when HbA1c and OGTT cannot be used. The study was published in the January 2019 issue of the journal Practical Laboratory Medicine.

Related Links:
Federal University of Minas Gerais


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Connectivity Solution
EKF Link
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: These images show breast tumors in a new preclinical model developed by Garvan researchers. The cells carry a fluorescent sensor that lights up blue/green when CDK1—the protein \'engine\' cells need to divide—is switched on. Using it, the team watched CDK1 activity rise as tumors became invasive and stay high in tumors that kept growing despite treatment. (Image Credit: Dr. Max Nobis / Garvan Institute)

Study Finds Potential Marker of Targeted Drug Resistance in Breast Cancer

Estrogen receptor-positive breast cancer is the most common breast cancer subtype and is driven by estrogen. Many patients are treated with CDK4/6 inhibitors alongside hormone therapy, but these drugs... Read more

Hematology

view channel
Image: Mayo Clinic researchers used genetic data from nearly 50,000 participants to identify sickle cell and beta-thalassemia carrier traits, highlighting how population-scale testing can complement existing screening (Image Credit: Adobe Stock)

Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification

Inherited hemoglobin disorders can affect oxygen transport, yet individuals who carry only a trait may remain unaware of their status. People with sickle cell trait or beta-thalassemia trait often have... Read more

Microbiology

view channel
Image: Four-quadrant streaking of fecal samples on chromogenic UTI agar shows various patterns of relative bacterial species abundance. The assorted shapes of the pinkish colonies indicate different E. coli strains. (Photo courtesy of Sokurenko Lab)

Stool Testing Predicts UTI Risk and Guides Antibiotic Selection

Urinary tract infections (UTIs) are a common reason for antibiotic prescribing in general medical practice and can be painful in postmenopausal women, sometimes progressing to kidney infection or life-threatening... Read more

Pathology

view channel
AI: Artificial intelligence; CNN: Convolutional neural networks; ResNet: Residual neural network. (Xing-hua Gao from The First Hospital of China Medical University, China Image Source Link: https://www.ovid.com/jnls/cmj/fulltext/10.1097/cm9.0000000000004154~deep-learning-based-computational-pathology-technologies)

Review Highlights Progress and Validation Needs for AI in Digital Pathology

Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more

Industry

view channel
Image: The ExaccType ESR1 dPCR Kit uses digital PCR technology to detect key ESR1 mutations associated with acquired resistance to endocrine therapy. (Photo courtesy of  BIOTYPE)

Collaboration Expands Access to Tests for Cancer Treatment Resistance and Toxicity Risk

Precision medicine in oncology relies on molecular testing to identify biomarkers that can help guide treatment decisions. In hormone receptor-positive, HER2-negative metastatic breast cancer, ESR1 mutations... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.